Aerie Pharmaceuticals

-$0.01 (-0.18%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AERI and other ETFs, options, and stocks.

About AERI

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.

CEO
Rajkumar Kannan
Employees
376
Headquarters
Durham, North Carolina
Founded
2005

AERI Key Statistics

Market cap
263.54M
Price-Earnings ratio
—
Dividend yield
—
Average volume
700.97K
High today
$5.51
Low today
$5.18
Open price
$5.42
Volume
918.50K
52 Week high
$19.26
52 Week low
$5.18

AERI News

BenzingaMay 24

Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study

Aerie Pharmaceuticals, Inc. AERI has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs

AERI Earnings

-$0.86
-$0.21
$0.44
$1.09
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 3, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure